| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8784889 | Advances in Radiation Oncology | 2018 | 26 Pages |
Abstract
Although most patients with stage II-III rectal cancer at queried National Cancer Institute-designated cancer centers between 2005 and 2011 received 3-dimensional CRT, significant and increasing numbers received IMRT. IMRT utilization is highly variable among institutions and not uniform among sociodemographic groups but may be more consistently embraced in specific clinical settings. Given this trend, comparative-effectiveness research is needed to evaluate the benefits of IMRT for rectal cancer.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Marsha MD, PhD, Joyce PhD, Anna MS, Tanios MD, Lily MD, Joshua E. MD, Steven J. MD, MS, Deborah MD, MPH, John M. MD, FACS, Al B. MD, Martin R. MD, Christopher H. MD, Karyn A. MD, MS,